Effects of travoprost 0.004% compared with latanoprost 0.005% on the intraocular pressure of normal dogs.
OBJECTIVE
To compare the effects of travoprost 0.004% and latanoprost 0.005% on the intraocular pressure (IOP) of normal dogs.


METHODS
Twenty mixed breed dogs were randomized to two groups: latanoprost was used in group A and travoprost in group B. The drugs were instilled in the right eye of the dogs, whereas the left eye received placebo. Both drugs were instilled once a day at 8 am during 5 days. IOP measurements were made at 8 am, 10 am, 2 pm and 8 pm during the 5 days of treatment, the 3 days that preceded treatment, and 3 days following treatment. Presence of blepharospasm, miosis, anterior chamber flare, and conjunctival hyperemia were evaluated during the study.


RESULTS
Mean IOP was significantly reduced in the eyes treated with both latanoprost and travoprost, when compared with the eyes treated with placebo (P<0.05). There was no statistically significant difference between the mean IOPs of eyes treated with latanoprost and travoprost at all time intervals during baseline, treatment, and recovery (P>0.05). On the fifth day of treatment and on the first day of the recovery period, a severe ocular hypotension was noted with both drugs, resulting in imprecise readings with the tonometer. Miosis and conjunctival hyperemia were observed in the treated eyes of both groups, whereas flare was noticed in one latanoprost-treated eye.


CONCLUSIONS
Travoprost 0.004% significantly reduces the IOP in normal dogs. The hypotensive effect obtained with travoprost 0.004% is comparable to that obtained with latanoprost 0.005%.
Carvalho
Alex B
AB
Department of Surgery, University of São Paulo, College of Veterinary Medicine, Brazil.
Laus
José L
JL
Costa
Vital P
VP
Barros
Paulo S M
PS
Silveira
Patrícia R
PR
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004285:Dogs; D005260:Female; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D011897:Random Allocation; D014065:Tonometry, Ocular / Q000379:methods / Q000662:veterinary*; D000069557:Travoprost
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069557:Travoprost